Marijuana use among patients with epilepsy at a tertiary care center

Alysse Kerr, Victoria Walston, Victoria Wong, Marissa Kellogg, Lia Ernst

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The expansion of medical and recreational marijuana legalization facilitates patient access to cannabis, and many patients with epilepsy pursue marijuana as a treatment for seizures. We administered a nine-item survey on marijuana use to patients seen in an epilepsy clinic over a 9 month period at a tertiary care center in Oregon where recreational use was legalized in 2015. The majority of respondents (n = 39) reported cannabis use for the purpose of treating epilepsy (87.2%, n = 34), and strongly agreed (53.8%, n = 21) or agreed (28.2%, n = 11) that cannabis use improved seizure control. The most commonly selected cannabis strains were high cannabidiol (CBD) (30.8%, n = 12) or multiple types (30.8%, n = 12), with administration methods of smoking (66.7%, n = 26), edibles (48.7%, n = 19), and concentrates (43.6%, n = 17). More participants reported using marijuana with primarily CBD than primarily tetrahydrocannabinol (THC) or equal CBD:THC content, and very few women reported using marijuana with primarily THC compared with men (10% of female versus 47% of male respondents). Only 2 of 39 participants were able to give an exact dosage used in milligrams. Medical and recreational dispensaries were the most common cannabis sources, followed by homegrown and friends/family members. Although pharmaceutical CBD extract is now Food and Drug Administration (FDA)-approved for certain epilepsy types, access remains limited. Further research is needed to understand recreational cannabis use among patients with epilepsy while clinical research for pharmaceutical cannabis products continues.

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalEpilepsy and Behavior
Volume97
DOIs
StatePublished - Aug 1 2019

Fingerprint

Cannabis
Tertiary Care Centers
Epilepsy
Cannabidiol
Dronabinol
Seizures
Medical Marijuana
United States Food and Drug Administration
Research
Pharmaceutical Preparations
Smoking

Keywords

  • Cannabidiol
  • Cannabis
  • Clinical survey
  • Epilepsy
  • Medical marijuana

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Marijuana use among patients with epilepsy at a tertiary care center. / Kerr, Alysse; Walston, Victoria; Wong, Victoria; Kellogg, Marissa; Ernst, Lia.

In: Epilepsy and Behavior, Vol. 97, 01.08.2019, p. 144-148.

Research output: Contribution to journalArticle

Kerr, Alysse ; Walston, Victoria ; Wong, Victoria ; Kellogg, Marissa ; Ernst, Lia. / Marijuana use among patients with epilepsy at a tertiary care center. In: Epilepsy and Behavior. 2019 ; Vol. 97. pp. 144-148.
@article{94fc2a1de4ea4c14887e30049dc8cb29,
title = "Marijuana use among patients with epilepsy at a tertiary care center",
abstract = "The expansion of medical and recreational marijuana legalization facilitates patient access to cannabis, and many patients with epilepsy pursue marijuana as a treatment for seizures. We administered a nine-item survey on marijuana use to patients seen in an epilepsy clinic over a 9 month period at a tertiary care center in Oregon where recreational use was legalized in 2015. The majority of respondents (n = 39) reported cannabis use for the purpose of treating epilepsy (87.2{\%}, n = 34), and strongly agreed (53.8{\%}, n = 21) or agreed (28.2{\%}, n = 11) that cannabis use improved seizure control. The most commonly selected cannabis strains were high cannabidiol (CBD) (30.8{\%}, n = 12) or multiple types (30.8{\%}, n = 12), with administration methods of smoking (66.7{\%}, n = 26), edibles (48.7{\%}, n = 19), and concentrates (43.6{\%}, n = 17). More participants reported using marijuana with primarily CBD than primarily tetrahydrocannabinol (THC) or equal CBD:THC content, and very few women reported using marijuana with primarily THC compared with men (10{\%} of female versus 47{\%} of male respondents). Only 2 of 39 participants were able to give an exact dosage used in milligrams. Medical and recreational dispensaries were the most common cannabis sources, followed by homegrown and friends/family members. Although pharmaceutical CBD extract is now Food and Drug Administration (FDA)-approved for certain epilepsy types, access remains limited. Further research is needed to understand recreational cannabis use among patients with epilepsy while clinical research for pharmaceutical cannabis products continues.",
keywords = "Cannabidiol, Cannabis, Clinical survey, Epilepsy, Medical marijuana",
author = "Alysse Kerr and Victoria Walston and Victoria Wong and Marissa Kellogg and Lia Ernst",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.yebeh.2019.05.037",
language = "English (US)",
volume = "97",
pages = "144--148",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Marijuana use among patients with epilepsy at a tertiary care center

AU - Kerr, Alysse

AU - Walston, Victoria

AU - Wong, Victoria

AU - Kellogg, Marissa

AU - Ernst, Lia

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The expansion of medical and recreational marijuana legalization facilitates patient access to cannabis, and many patients with epilepsy pursue marijuana as a treatment for seizures. We administered a nine-item survey on marijuana use to patients seen in an epilepsy clinic over a 9 month period at a tertiary care center in Oregon where recreational use was legalized in 2015. The majority of respondents (n = 39) reported cannabis use for the purpose of treating epilepsy (87.2%, n = 34), and strongly agreed (53.8%, n = 21) or agreed (28.2%, n = 11) that cannabis use improved seizure control. The most commonly selected cannabis strains were high cannabidiol (CBD) (30.8%, n = 12) or multiple types (30.8%, n = 12), with administration methods of smoking (66.7%, n = 26), edibles (48.7%, n = 19), and concentrates (43.6%, n = 17). More participants reported using marijuana with primarily CBD than primarily tetrahydrocannabinol (THC) or equal CBD:THC content, and very few women reported using marijuana with primarily THC compared with men (10% of female versus 47% of male respondents). Only 2 of 39 participants were able to give an exact dosage used in milligrams. Medical and recreational dispensaries were the most common cannabis sources, followed by homegrown and friends/family members. Although pharmaceutical CBD extract is now Food and Drug Administration (FDA)-approved for certain epilepsy types, access remains limited. Further research is needed to understand recreational cannabis use among patients with epilepsy while clinical research for pharmaceutical cannabis products continues.

AB - The expansion of medical and recreational marijuana legalization facilitates patient access to cannabis, and many patients with epilepsy pursue marijuana as a treatment for seizures. We administered a nine-item survey on marijuana use to patients seen in an epilepsy clinic over a 9 month period at a tertiary care center in Oregon where recreational use was legalized in 2015. The majority of respondents (n = 39) reported cannabis use for the purpose of treating epilepsy (87.2%, n = 34), and strongly agreed (53.8%, n = 21) or agreed (28.2%, n = 11) that cannabis use improved seizure control. The most commonly selected cannabis strains were high cannabidiol (CBD) (30.8%, n = 12) or multiple types (30.8%, n = 12), with administration methods of smoking (66.7%, n = 26), edibles (48.7%, n = 19), and concentrates (43.6%, n = 17). More participants reported using marijuana with primarily CBD than primarily tetrahydrocannabinol (THC) or equal CBD:THC content, and very few women reported using marijuana with primarily THC compared with men (10% of female versus 47% of male respondents). Only 2 of 39 participants were able to give an exact dosage used in milligrams. Medical and recreational dispensaries were the most common cannabis sources, followed by homegrown and friends/family members. Although pharmaceutical CBD extract is now Food and Drug Administration (FDA)-approved for certain epilepsy types, access remains limited. Further research is needed to understand recreational cannabis use among patients with epilepsy while clinical research for pharmaceutical cannabis products continues.

KW - Cannabidiol

KW - Cannabis

KW - Clinical survey

KW - Epilepsy

KW - Medical marijuana

UR - http://www.scopus.com/inward/record.url?scp=85067826230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067826230&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2019.05.037

DO - 10.1016/j.yebeh.2019.05.037

M3 - Article

AN - SCOPUS:85067826230

VL - 97

SP - 144

EP - 148

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -